NASDAQ:GALT - Galectin Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.55 -0.11 (-2.36 %) (As of 05/19/2019 10:20 AM ET)Previous Close$4.55Today's Range$4.50 - $4.735052-Week Range$3.17 - $9.49Volume181,032 shsAverage Volume366,382 shsMarket Capitalization$207.43 millionP/E RatioN/ADividend YieldN/ABeta3.54 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia. Receive GALT News and Ratings via Email Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GALT Previous Symbol CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone678-620-3186Debt Debt-to-Equity RatioN/A Current Ratio8.25 Quick Ratio4.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book45.50Profitability EPS (Most Recent Fiscal Year)($0.38) Net Income$-13,900,000.00 Net MarginsN/A Return on Equity-1,599.05% Return on Assets-139.74%Miscellaneous Employees6 Outstanding Shares45,590,000Market Cap$207.43 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions What is Galectin Therapeutics' stock symbol? Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT." How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Wednesday, March, 6th. The company reported ($0.08) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.08). View Galectin Therapeutics' Earnings History. When is Galectin Therapeutics' next earnings date? Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Galectin Therapeutics. What price target have analysts set for GALT? 2 brokers have issued 1-year price targets for Galectin Therapeutics' shares. Their forecasts range from $11.00 to $12.00. On average, they expect Galectin Therapeutics' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price. View Analyst Price Targets for Galectin Therapeutics. What is the consensus analysts' recommendation for Galectin Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galectin Therapeutics. Has Galectin Therapeutics been receiving favorable news coverage? News stories about GALT stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Galectin Therapeutics earned a daily sentiment score of 2.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Galectin Therapeutics' key competitors? Some companies that are related to Galectin Therapeutics include Dicerna Pharmaceuticals (DRNA), Kiniksa Pharmaceuticals (KNSA), Vanda Pharmaceuticals (VNDA), TherapeuticsMD (TXMD), Retrophin (RTRX), CannTrust (CNTTF), Axsome Therapeutics (AXSM), Principia Biopharma (PRNB), Cara Therapeutics (CARA), Eagle Pharmaceuticals (EGRX), ArQule (ARQL), Y-mAbs Therapeutics (YMAB), ChemoCentryx (CCXI), Arvinas (ARVN) and Vectura Group (VEGPF). What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Intercept Pharmaceuticals (ICPT), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Verastem (VSTM), Novavax (NVAX) and Viking Therapeutics (VKTX). Who are Galectin Therapeutics' key executives? Galectin Therapeutics' management team includes the folowing people: Dr. Harold H. Shlevin, Pres & CEO (Age 69)Mr. Jack W. Callicutt, CFO & Sec. (Age 52)Robert Tritt, Gen. CounselDr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49) Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Advisor Group Inc. (1.52%), BlackRock Inc. (1.31%), JPMorgan Chase & Co. (0.41%), Cambridge Investment Research Advisors Inc. (0.39%), Laurion Capital Management LP (0.38%) and Northern Trust Corp (0.20%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber, Richard E Uihlein and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics. Which institutional investors are selling Galectin Therapeutics stock? GALT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., MML Investors Services LLC, Alpine Global Management LLC and Morgan Stanley. Company insiders that have sold Galectin Therapeutics company stock in the last year include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Marc Rubin and Peter G Traber. View Insider Buying and Selling for Galectin Therapeutics. Which institutional investors are buying Galectin Therapeutics stock? GALT stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Cambridge Investment Research Advisors Inc., Laurion Capital Management LP, Tibra Equities Europe Ltd, Citigroup Inc., ExodusPoint Capital Management LP, Jefferies Group LLC and Jane Street Group LLC. Company insiders that have bought Galectin Therapeutics stock in the last two years include Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Richard E Uihlein and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics. How do I buy shares of Galectin Therapeutics? Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Galectin Therapeutics' stock price today? One share of GALT stock can currently be purchased for approximately $4.55. How big of a company is Galectin Therapeutics? Galectin Therapeutics has a market capitalization of $207.43 million. The company earns $-13,900,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe. What is Galectin Therapeutics' official website? The official website for Galectin Therapeutics is http://www.galectintherapeutics.com. How can I contact Galectin Therapeutics? Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected] MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 275 (Vote Outperform)Underperform Votes: 232 (Vote Underperform)Total Votes: 507MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe GALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.